Home > Insider Trading > Filing (0001104659-15-049022)

Filing Details

Accession Number:: 0001104659-15-049022
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-06-30 18:47:33
Reporting Period:: 2015-06-30

Filing Date:: 2015-06-30
Accepted Time:: 2015-06-30 18:47:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1454789	Catabasis Pharmaceuticals Inc	CATB	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1252522	Nicholas Galakatos	C/O Clarus Ventures, Llc 101 Main Street Suite 1210 Cambridge MA 02142		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-06-30	1,618,676	$0.00	1,618,676	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-06-30	757,117	$0.00	2,375,793	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-06-30	376,695	$12.00	2,752,488	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2015-06-30	20,800,000	$0.00	1,618,676	$0.00
Common Stock	Series B Preferred Stock	Disposition	2015-06-30	9,728,971	$0.00	757,117	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2015-06-30	11,094	$0.00	11,094	$12.21

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
11,094	2025-06-29	No	4	A	Direct

Footnotes

The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus.
The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Dr. Galakatos, Denis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Galakatos disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.
This option was granted on June 30, 2015 and vests over three years, with one-third of the shares vesting on each anniversary of the grant date until the third anniversary of the grant date.